Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Opinion statement Treatment of transthyretin familial amyloid polyneuropathy (TTR FAP)
must be tailored to disease stage. Patients with early stage disease (ie, without major …

Background Hereditary transthyretin (ATTRv, v for variant) amyloidosis with polyneuropathy
is a rare disease caused by mutations in the transthyretin gene. In ATTRv amyloidosis …

Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive disease caused by
mutations in the TTR gene leading to multisystem organ dysfunction. Pathogenic TTR …

Hereditary transthyretin amyloidosis (ATTRv) is a severe, adult-onset autosomal dominant
inherited systemic disease predominantly affecting the peripheral and autonomic nervous …

Hereditary transthyretin amyloidosis (hATTR) with polyneuropathy (formerly known as
Familial Amyloid Polyneuropathy) is a rare disease due to mutations in the gene encoding …

Background Transthyretin hereditary (familial) amyloid polyneuropathy (TTR-FAP) was first
identified in Portugal in 1952 [Citation 1]. In 1984, the first report of a causative mutation …

Hereditary transthyretin amyloidosis is caused by pathogenic variants (ATTR v) in the TTR
gene. Alongside cardiac dysfunction, the disease typically manifests with a severely …

Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is a rare,
progressive, fatal multi-systemic disease, autosomal dominantly inherited with …

Hereditary amyloidogenic transthyretin (ATTRv) amyloidosis with polyneuropathy (also
known as familial amyloid polyneuropathy) is a condition with adult onset caused by …